Screener
Integra LifeSciences IART Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Depreciation and amortization | 76,565 | 74,880 |
| Non-cash impairment charges | — | 511,365 |
| Deferred income tax provision (benefit) | (3,007) | (46,663) |
| Share-based compensation | 11,009 | 7,165 |
| Amortization of debt issuance costs and expenses associated with debt refinancing | 2,015 | 3,275 |
| Non-cash lease adjustment | 2,948 | (599) |
| Loss on disposal of property and equipment | 733 | 494 |
| Change in fair value of contingent consideration and others | (774) | (203) |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's stock-based comp?
- Integra LifeSciences (IART) reported stock-based comp of $5.84M in Q2 2026.
- How has Integra LifeSciences's stock-based comp changed year-over-year?
- Integra LifeSciences's stock-based comp increased by 10.4% year-over-year, from $5.3M to $5.84M.
- What is the long-term trend for Integra LifeSciences's stock-based comp?
- Over 4 years (2021 to 2025), Integra LifeSciences's stock-based comp has grown at a -15.4% compound annual growth rate (CAGR), from $36.21M to $18.58M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Integra LifeSciences's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude